Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics, Inc. (NASDAQ: MYGN) generates frequent news as a molecular diagnostic testing and precision medicine company. Its announcements often cover financial results, clinical research, product updates, and collaborations that shape how genetic and genomic testing is used in oncology, women’s health, and mental health care.
Investors and clinicians following MYGN news will see regular earnings releases and financial guidance updates, which the company also furnishes on Form 8-K. These updates describe trends in hereditary cancer testing, tumor profiling, prenatal screening, and pharmacogenomics, along with commentary on business performance and strategic priorities.
Scientific and medical conference activity is another major source of news. Myriad Genetics frequently reports new data on tests such as the MyRisk Hereditary Cancer Test, Precise MRD, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, Foresight Carrier Screen, and the GeneSight Psychotropic test. Company communications highlight abstracts and posters at meetings like the San Antonio Breast Cancer Symposium and the National Society of Genetic Counselors Annual Conference.
News items also describe collaborations with partners including SOPHiA GENETICS, Clairity, and MagView, focused on areas such as liquid biopsy companion diagnostics and integrated breast cancer risk assessment platforms. Updates on leadership changes, credit facilities, and conference presentations at investor healthcare events are also part of the MYGN news flow.
This page provides a centralized view of these developments so readers can review Myriad Genetics’ latest financial disclosures, research milestones, product enhancements, and partnership announcements in one place.
Myriad Genetics (NASDAQ: MYGN) will present six abstracts at ASCO-GU Feb 26-28, 2026 reporting clinical performance for Precise MRD, Prolaris, and MyRisk oncology tests. Key data include ultra-sensitive ctDNA detection (below 100 ppm), a meta-analysis of 14 studies >8,000 patients showing Prolaris prognostic power, and germline testing results across Gleason and NCCN risk groups.
Findings are largely interim or preliminary but indicate potential diagnostic and prognostic value across genitourinary cancers.
Myriad Genetics (NASDAQ: MYGN) reported Q4 2025 revenue of $209.8 million and full‑year 2025 revenue of $824.5 million (down 2% YoY). Test volume was 382,000 in Q4, up 2% YoY. Q4 GAAP net loss was $7.9 million; adjusted EBITDA was $14.3 million. The company reiterated 2026 guidance of $860–$880 million revenue and 68–69% adjusted gross margin, with adjusted EBITDA guidance of $37–$49 million.
Management highlighted Prolaris, GeneSight, and three planned 2026 test launches (Precise MRD, AI-enabled Prolaris, FirstGene) as drivers for growth.
Myriad Genetics (NASDAQ: MYGN) announced publication of the analytical validation of the FirstGene Multiple Prenatal Screen in Clinical Chemistry on February 19, 2026. Using nearly 500 samples, the study reported each test component achieved ≥98.2% analytical sensitivity and ≥99.0% analytical specificity.
The assay evaluates fetal aneuploidy, RhD compatibility, and recessive condition status for the pregnant person and fetus across 19 prevalent severe conditions. The test uses fetal-fraction amplification and a trajectory analysis algorithm to improve genotype resolution and reproducibility, which the company says supports broader commercialization efforts.
Myriad Genetics (NASDAQ: MYGN) will release its fourth quarter and full year 2025 financial results and hold an earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The earnings release will be issued after market close the same day.
Management will provide a financial overview and business update; a live webcast and archived replay will be available at the company's Investor Relations website. Company executives will also appear at three investor healthcare conferences in March 2026.
Myriad Genetics (NASDAQ: MYGN) plans a limited clinical launch of Precise MRD in March 2026, starting with breast cancer and expanding to colorectal and renal cancers later in 2026, with potential further expansion in 2027.
Key study data show ultrasensitive ctDNA detection down to 1 part-per-million, 93% baseline sensitivity in MONITOR-Breast, and 100% baseline detection plus 100% one-month post-surgery sensitivity for recurrence prediction in MONSTAR-SCREEN-3; one-month postoperative ctDNA positivity was linked to shorter disease-free survival (median follow-up ~6 months, p<0.001).
Myriad Genetics (NASDAQ: MYGN) released select unaudited preliminary results for Q4 and full year 2025 and introduced full‑year 2026 guidance on Jan 12, 2026.
Preliminary revenue: Q4 2025 $207M–$209M; full year 2025 $822M–$824M. 2026 guidance: Revenue $860M–$880M, Adjusted Gross Margin 68%–69%, and Adjusted EBITDA $37M–$49M. The company will publish final audited results in February 2026 and host a webcast on Jan 14, 2026 at 5:15 pm PT.
Myriad Genetics (NASDAQ: MYGN) announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026 at 5:15 pm PT (8:15 pm ET). The presentation will be available via a live webcast and an archived replay at the company’s investor website: investor.myriad.com.
Myriad Genetics (NASDAQ: MYGN) announced it will present 8 abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Dec. 10–11, 2025, covering MRD, germline testing, somatic profiling, and polygenic risk.
Key highlights include new data on the Precise Molecular Residual Disease (MRD) Test—a tumor-informed, WGS-based assay with custom selection of up to 1,000 variants and reported ultra-sensitivity at low tumor fractions (RUO)—and updates to the MyRisk Hereditary Cancer Test expanded to 63 genes. Myriad will sponsor a Product Theater session on Dec. 10 (2:30–3:30 p.m. CST) and host a booth (#1414) during exhibition hours.
Myriad Genetics (NASDAQ: MYGN), Clairity, and MagView announced a collaboration on Nov 25, 2025 to deliver the first integrated platform combining genotype and AI-derived phenotype for breast cancer risk assessment.
The integration links Myriad’s MyRisk with RiskScore hereditary cancer test, Clairity Breast (the FDA-authorized AI mammogram risk estimator), and MagView’s Luminary Risk workflow to provide clinicians a unified, actionable view of five-year breast cancer risk from routine mammograms and genetics.
The partners say the platform aims to identify more women at elevated risk and support earlier, personalized interventions while preserving clinical workflow efficiency.
Myriad Genetics (NASDAQ: MYGN) said its management will participate in two investor healthcare conferences in late 2025. Wolfe Research Healthcare Conference — fireside chat on Nov. 18, 2025 at 1:20 pm ET. Piper Sandler Healthcare Conference — fireside chat on Dec. 2, 2025 at 12:00 pm ET. Both presentations will be available via live audio webcasts in the investor information section at investor.myriad.com.